WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) has shown a trend toward improving overall survival (OS) compared with chemotherapy in a Phase III trial for certain lung cancer patients. The study, TROPION-Lung01, involved adults with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who had previously undergone at least one line of therapy.
In the overall trial population, OS results numerically favored Dato-DXd over docetaxel (12.9 vs. 11.8 months), although the difference did not reach statistical significance. A prespecified subgroup of patients with nonsquamous NSCLC showed a 2.3-month improvement in OS for those treated with Dato-DXd versus docetaxel (14.6 vs. 12.3 months). These findings were presented at the IASLC 2024 World Conference on Lung Cancer.
Dato-DXd is a TROP2-directed antibody drug conjugate, developed by Daiichi Sankyo and jointly advanced by AstraZeneca and Daiichi Sankyo. The safety profile of Dato-DXd was consistent with previous analyses, showing lower rates of dose reduction and discontinuation due to adverse events compared to docetaxel.
Dr. Jacob Sands, an investigator in the trial from the Dana-Farber Cancer Institute, highlighted the significance of the results, noting that datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival along with an improved response rate and duration of response.
Susan Galbraith from AstraZeneca and Ken Takeshita from Daiichi Sankyo expressed optimism about the role of datopotamab deruxtecan in treating different stages of non-small cell lung cancer. The data from the trial supports ongoing reviews by health authorities for this indication.
In another study, the NeoCOAST-2 trial, datopotamab deruxtecan combined with IMFINZI (durvalumab) and chemotherapy showed promising response rates in patients with early-stage resectable NSCLC. The trial is part of a comprehensive development program that includes more than 20 trials across multiple cancers.
The information presented in this article is based on a press release statement from AstraZeneca.
In other recent news, AstraZeneca announced a significant update on its cancer drug, IMFINZI (durvalumab), which has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults with resectable early-stage non-small cell lung cancer (NSCLC). This decision was based on the AEGEAN Phase III trial, which demonstrated a 32% reduction in the risk of disease recurrence or death compared to chemotherapy alone. Concurrently, IMFINZI has been granted Priority Review status by the FDA for treating limited-stage small cell lung cancer, following the successful results from the ADRIATIC Phase III trial.
On the financial front, AstraZeneca secured €1.4 billion through a bond offering managed by BNP Paribas (OTC:BNPQY), Goldman Sachs International, Morgan Stanley, and Société Générale. The company also received a vote of confidence from TD Cowen, which raised its stock price target on AstraZeneca's shares to $95 from the previous target of $90, while maintaining a Buy rating.
In terms of governance, AstraZeneca disclosed its total number of voting rights and share capital as of the end of August, in compliance with the UK's Financial Conduct Authority's Disclosure and Transparency Rules. The total number of voting rights in the company equals the number of shares, as no shares are currently held in treasury. These are the latest developments in the ongoing advancements and achievements of AstraZeneca.
InvestingPro Insights
As AstraZeneca (NASDAQ: AZN) continues to explore innovative treatments in the fight against lung cancer, the company's financial health remains a key consideration for investors. According to real-time data from InvestingPro, AstraZeneca boasts a substantial market capitalization of $256.76 billion, underscoring its significant presence in the pharmaceutical industry. While the company's P/E ratio stands at 39.83, indicating a premium valuation, this figure is more moderate when adjusted for the last twelve months as of Q2 2024, at 28.1.
InvestingPro Tips highlight that AstraZeneca's net income is expected to grow this year, a positive signal for potential investors. Moreover, two analysts have revised their earnings estimates upwards for the upcoming period, suggesting confidence in the company's financial trajectory. These insights are particularly relevant as AstraZeneca's collaboration with Daiichi Sankyo on datopotamab deruxtecan could impact future revenue streams and profitability.
Additionally, AstraZeneca's revenue has shown a healthy growth of 10.45% in the last twelve months as of Q2 2024, with a quarterly increase of 13.33% in Q2 2024. This growth trajectory may reflect the company's innovative pipeline and successful commercialization of new therapies. For those interested in further insights, InvestingPro offers a total of 15 additional InvestingPro Tips for AstraZeneca, available at https://www.investing.com/pro/AZN, providing a comprehensive analysis of the company's financial and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.